

# Lymphangiomyomatosis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/L8C08AAB8A36EN.html>

Date: May 2024

Pages: 135

Price: US\$ 6,499.00 (Single User License)

ID: L8C08AAB8A36EN

## Abstracts

The 7 major lymphangiomyomatosis markets reached a value of US\$ 87.9 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US\$ 125.5 Million by 2034, exhibiting a growth rate (CAGR) of 3.29% during 2024-2034.

The lymphangiomyomatosis market has been comprehensively analyzed in IMARC's new report titled "Lymphangiomyomatosis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034".

Lymphangiomyomatosis (LAM) refers to a rare and progressive lung disease that mainly affects females of childbearing age. It is characterized by an abnormal growth of smooth muscle cells, primarily in the lungs but also involving various other organs like the kidneys and lymphatics. The symptoms of LAM can vary widely, but they often include shortness of breath, coughing, wheezing, chest pain, and recurrent lung collapses. These indications stem from the constriction and blockage of airways as well as the formation of cysts in the lungs, leading to impaired lung function and reduced oxygen exchange. The diagnosis of LAM typically involves a combination of clinical evaluation, lung function tests, high-resolution CT scans, and occasionally a lung biopsy to confirm the presence of characteristic smooth muscle cell overgrowth. Additionally, genetic testing and monitoring of kidney function may be necessary, as LAM can be associated with several other genetic disorders.

The increasing prevalence of somatic mutations in the TSC1 and TSC2 genes that cause abnormal growth of smooth muscle cells, particularly in the lungs, leading to the constriction of airways and impairing respiratory function, is primarily driving the lymphangiomyomatosis market. In addition to this, the inflating utilization of effective therapeutic interventions, including mTOR inhibitors, hormone therapy, and lung

transplantation, aimed at managing symptoms and halting disease progression, is also creating a positive outlook for the market. Moreover, the widespread adoption of pulmonary rehabilitation programs, a comprehensive approach encompassing physical exercises and breathing techniques, to help in enhancing lung capacity, boosting physical endurance, and improving overall quality of life, is further bolstering the market growth. Apart from this, the rising usage of minimally invasive procedures, such as bronchoscopic interventions, since they can alleviate airway obstructions and promote breathing efficiency in patients, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of targeted therapies, which address the specific molecular pathways and mechanisms underlying the ailment, is also augmenting the market growth. Furthermore, the escalating application of genetic therapies, where innovative strategies involving the manipulation of genetic material offer a potential avenue for correcting or compensating the defective TSC1 and TSC2 genes, is expected to drive the lymphangioleiomyomatosis market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the lymphangioleiomyomatosis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for lymphangioleiomyomatosis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the lymphangioleiomyomatosis market in any manner.

### Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

### Countries Covered

United States

Germany

France  
United Kingdom  
Italy  
Spain  
Japan

### Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario  
Historical, current, and future performance of the lymphangioleiomyomatosis market  
Historical, current, and future performance of various therapeutic categories in the market

Sales of various drugs across the lymphangioleiomyomatosis market

Reimbursement scenario in the market

In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current lymphangioleiomyomatosis marketed drugs and late-stage pipeline drugs.

### In-Market Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

### Late-Stage Pipeline Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

\*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

### Key Questions Answered in this Report:

*Lymphangioleiomyomatosis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast...*

## Market Insights

How has the lymphangioliomyomatosis market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the lymphangioliomyomatosis market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the lymphangioliomyomatosis market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

## Epidemiology Insights

What is the number of prevalent cases (2018-2034) of lymphangioliomyomatosis across the seven major markets?

What is the number of prevalent cases (2018-2034) of lymphangioliomyomatosis by age across the seven major markets?

What is the number of prevalent cases (2018-2034) of lymphangioliomyomatosis by gender across the seven major markets?

How many patients are diagnosed (2018-2034) with lymphangioliomyomatosis across the seven major markets?

What is the size of the lymphangioliomyomatosis patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of lymphangioliomyomatosis?

What will be the growth rate of patients across the seven major markets?

## Lymphangioliomyomatosis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for lymphangioliomyomatosis drugs across

the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the lymphangiomyomatosis market?

What are the key regulatory events related to the lymphangiomyomatosis market?

What is the structure of clinical trial landscape by status related to the lymphangiomyomatosis market?

What is the structure of clinical trial landscape by phase related to the lymphangiomyomatosis market?

What is the structure of clinical trial landscape by route of administration related to the lymphangiomyomatosis market?

## Contents

### **1 PREFACE**

### **2 SCOPE AND METHODOLOGY**

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
  - 2.3.1 Primary Sources
  - 2.3.2 Secondary Sources
- 2.4 Market Estimation
  - 2.4.1 Bottom-Up Approach
  - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

### **3 EXECUTIVE SUMMARY**

### **4 LYMPHANGIOLEIOMYOMATOSIS - INTRODUCTION**

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

### **5 LYMPHANGIOLEIOMYOMATOSIS - DISEASE OVERVIEW**

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

### **6 PATIENT JOURNEY**

### **7 LYMPHANGIOLEIOMYOMATOSIS - EPIDEMIOLOGY AND PATIENT POPULATION**

- 7.1 Epidemiology - Key Insights
- 7.2 Epidemiology Scenario - Top 7 Markets
  - 7.2.1 Epidemiology Scenario (2018-2023)
  - 7.2.2 Epidemiology Forecast (2024-2034)
  - 7.2.3 Epidemiology by Age (2018-2034)
  - 7.2.4 Epidemiology by Gender (2018-2034)
  - 7.2.5 Diagnosed Cases (2018-2034)
  - 7.2.6 Patient Pool/Treated Cases (2018-2034)
- 7.3 Epidemiology Scenario - United States
  - 7.3.1 Epidemiology Scenario (2018-2023)
  - 7.3.2 Epidemiology Forecast (2024-2034)
  - 7.3.3 Epidemiology by Age (2018-2034)
  - 7.3.4 Epidemiology by Gender (2018-2034)
  - 7.3.5 Diagnosed Cases (2018-2034)
  - 7.3.6 Patient Pool/Treated Cases (2018-2034)
- 7.4 Epidemiology Scenario - Germany
  - 7.4.1 Epidemiology Scenario (2018-2023)
  - 7.4.2 Epidemiology Forecast (2024-2034)
  - 7.4.3 Epidemiology by Age (2018-2034)
  - 7.4.4 Epidemiology by Gender (2018-2034)
  - 7.4.5 Diagnosed Cases (2018-2034)
  - 7.4.6 Patient Pool/Treated Cases (2018-2034)
- 7.5 Epidemiology Scenario - France
  - 7.5.1 Epidemiology Scenario (2018-2023)
  - 7.5.2 Epidemiology Forecast (2024-2034)
  - 7.5.3 Epidemiology by Age (2018-2034)
  - 7.5.4 Epidemiology by Gender (2018-2034)
  - 7.5.5 Diagnosed Cases (2018-2034)
  - 7.5.6 Patient Pool/Treated Cases (2018-2034)
- 7.6 Epidemiology Scenario - United Kingdom
  - 7.6.1 Epidemiology Scenario (2018-2023)
  - 7.6.2 Epidemiology Forecast (2024-2034)
  - 7.6.3 Epidemiology by Age (2018-2034)
  - 7.6.4 Epidemiology by Gender (2018-2034)
  - 7.6.5 Diagnosed Cases (2018-2034)
  - 7.6.6 Patient Pool/Treated Cases (2018-2034)
- 7.7 Epidemiology Scenario - Italy
  - 7.7.1 Epidemiology Scenario (2018-2023)
  - 7.7.2 Epidemiology Forecast (2024-2034)

- 7.7.3 Epidemiology by Age (2018-2034)
- 7.7.4 Epidemiology by Gender (2018-2034)
- 7.7.5 Diagnosed Cases (2018-2034)
- 7.7.6 Patient Pool/Treated Cases (2018-2034)
- 7.8 Epidemiology Scenario - Spain
  - 7.8.1 Epidemiology Scenario (2018-2023)
  - 7.8.2 Epidemiology Forecast (2024-2034)
  - 7.8.3 Epidemiology by Age (2018-2034)
  - 7.8.4 Epidemiology by Gender (2018-2034)
  - 7.8.5 Diagnosed Cases (2018-2034)
  - 7.8.6 Patient Pool/Treated Cases (2018-2034)
- 7.9 Epidemiology Scenario - Japan
  - 7.9.1 Epidemiology Scenario (2018-2023)
  - 7.9.2 Epidemiology Forecast (2024-2034)
  - 7.9.3 Epidemiology by Age (2018-2034)
  - 7.9.4 Epidemiology by Gender (2018-2034)
  - 7.9.5 Diagnosed Cases (2018-2034)
  - 7.9.6 Patient Pool/Treated Cases (2018-2034)

## **8 LYMPHANGIOLEIOMYOMATOSIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES**

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

## **9 LYMPHANGIOLEIOMYOMATOSIS - UNMET NEEDS**

## **10 LYMPHANGIOLEIOMYOMATOSIS - KEY ENDPOINTS OF TREATMENT**

## **11 LYMPHANGIOLEIOMYOMATOSIS - MARKETED PRODUCTS**

- 11.1 List of Lymphangioliomyomatosis Marketed Drugs Across the Top 7 Markets
  - 11.1.1 Rapamune (Sirolimus) – Pfizer
    - 11.1.1.1 Drug Overview
    - 11.1.1.2 Mechanism of Action
    - 11.1.1.3 Regulatory Status
    - 11.1.1.4 Clinical Trial Results
    - 11.1.1.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the



complete list has been provided in the report.

## **12 LYMPHANGIOLEIOMYOMATOSIS - PIPELINE DRUGS**

### 12.1 List of Lymphangiomyomatosis Pipeline Drugs Across the Top 7 Markets

#### 12.1.1 Drug Name – Company Name

##### 12.1.1.1 Drug Overview

##### 12.1.1.2 Mechanism of Action

##### 12.1.1.3 Clinical Trial Results

##### 12.1.1.4 Safety and Efficacy

##### 12.1.1.5 Regulatory Status

Kindly note that the complete list of pipeline drugs has been provided in the report.

## **13. LYMPHANGIOLEIOMYOMATOSIS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS**

## **14. LYMPHANGIOLEIOMYOMATOSIS – CLINICAL TRIAL LANDSCAPE**

### 14.1 Drugs by Status

### 14.2 Drugs by Phase

### 14.3 Drugs by Route of Administration

### 14.4 Key Regulatory Events

## **15 LYMPHANGIOLEIOMYOMATOSIS - MARKET SCENARIO**

### 15.1 Market Scenario - Key Insights

### 15.2 Market Scenario - Top 7 Markets

#### 15.2.1 Lymphangiomyomatosis - Market Size

##### 15.2.1.1 Market Size (2018-2023)

##### 15.2.1.2 Market Forecast (2024-2034)

#### 15.2.2 Lymphangiomyomatosis - Market Size by Therapies

##### 15.2.2.1 Market Size by Therapies (2018-2023)

##### 15.2.2.2 Market Forecast by Therapies (2024-2034)

### 15.3 Market Scenario - United States

#### 15.3.1 Lymphangiomyomatosis - Market Size

##### 15.3.1.1 Market Size (2018-2023)

##### 15.3.1.2 Market Forecast (2024-2034)

#### 15.3.2 Lymphangiomyomatosis - Market Size by Therapies

##### 15.3.2.1 Market Size by Therapies (2018-2023)

- 15.3.2.2 Market Forecast by Therapies (2024-2034)
- 15.3.3 Lymphangioliomyomatosis - Access and Reimbursement Overview
- 15.4 Market Scenario - Germany
  - 15.4.1 Lymphangioliomyomatosis - Market Size
    - 15.4.1.1 Market Size (2018-2023)
    - 15.4.1.2 Market Forecast (2024-2034)
  - 15.4.2 Lymphangioliomyomatosis - Market Size by Therapies
    - 15.4.2.1 Market Size by Therapies (2018-2023)
    - 15.4.2.2 Market Forecast by Therapies (2024-2034)
  - 15.4.3 Lymphangioliomyomatosis - Access and Reimbursement Overview
- 15.5 Market Scenario - France
  - 15.5.1 Lymphangioliomyomatosis - Market Size
    - 15.5.1.1 Market Size (2018-2023)
    - 15.5.1.2 Market Forecast (2024-2034)
  - 15.5.2 Lymphangioliomyomatosis - Market Size by Therapies
    - 15.5.2.1 Market Size by Therapies (2018-2023)
    - 15.5.2.2 Market Forecast by Therapies (2024-2034)
  - 15.5.3 Lymphangioliomyomatosis - Access and Reimbursement Overview
- 15.6 Market Scenario - United Kingdom
  - 15.6.1 Lymphangioliomyomatosis - Market Size
    - 15.6.1.1 Market Size (2018-2023)
    - 15.6.1.2 Market Forecast (2024-2034)
  - 15.6.2 Lymphangioliomyomatosis - Market Size by Therapies
    - 15.6.2.1 Market Size by Therapies (2018-2023)
    - 15.6.2.2 Market Forecast by Therapies (2024-2034)
  - 15.6.3 Lymphangioliomyomatosis - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
  - 15.7.1 Lymphangioliomyomatosis - Market Size
    - 15.7.1.1 Market Size (2018-2023)
    - 15.7.1.2 Market Forecast (2024-2034)
  - 15.7.2 Lymphangioliomyomatosis - Market Size by Therapies
    - 15.7.2.1 Market Size by Therapies (2018-2023)
    - 15.7.2.2 Market Forecast by Therapies (2024-2034)
  - 15.7.3 Lymphangioliomyomatosis - Access and Reimbursement Overview
- 15.8 Market Scenario - Spain
  - 15.8.1 Lymphangioliomyomatosis - Market Size
    - 15.8.1.1 Market Size (2018-2023)
    - 15.8.1.2 Market Forecast (2024-2034)
  - 15.8.2 Lymphangioliomyomatosis - Market Size by Therapies

- 15.8.2.1 Market Size by Therapies (2018-2023)
- 15.8.2.2 Market Forecast by Therapies (2024-2034)
- 15.8.3 Lymphangiomyomatosis - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
  - 15.9.1 Lymphangiomyomatosis - Market Size
    - 15.9.1.1 Market Size (2018-2023)
    - 15.9.1.2 Market Forecast (2024-2034)
  - 15.9.2 Lymphangiomyomatosis - Market Size by Therapies
    - 15.9.2.1 Market Size by Therapies (2018-2023)
    - 15.9.2.2 Market Forecast by Therapies (2024-2034)
  - 15.9.3 Lymphangiomyomatosis - Access and Reimbursement Overview

## **16 LYMPHANGIOLEIOMYOMATOSIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS**

## **17 LYMPHANGIOLEIOMYOMATOSIS MARKET - SWOT ANALYSIS**

- 17.1 Strengths
- 17.2 Weaknesses
- 17.3 Opportunities
- 17.4 Threats

## **18 LYMPHANGIOLEIOMYOMATOSIS MARKET – STRATEGIC RECOMMENDATIONS**

## **19 APPENDIX**

## I would like to order

Product name: Lymphangi leiomyomatosis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/L8C08AAB8A36EN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/L8C08AAB8A36EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

